sex hormones in coronavirus

The use of sex hormones in the control of coronavirus inflammation

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20150716023235N15

Enrollment

Registered

2020-05-29

Start date

2020-05-21

Completion date

Unknown

Last updated

2020-06-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Severity of COVID-19. Coronavirus infection, unspecified

Interventions

Intervention 1: Intervention group: COVID-19 Patients with respiratory, heart, or kidney failure over 50 years of age in addition to conventional therapies received Depo– testosterone vial 200 ng/ml p

Eligibility

Sex/Gender

All

Age

50 Years to No maximum

Inclusion criteria

Inclusion criteria: COVID-19 patients with respiratory, heart or kidney failure

Exclusion criteria

Exclusion criteria: History of breast cancer in females History of prostate cancer in males History of thromboembolism in both sexes Suspected breast examination in women High PSA in primary laboratory tests

Design outcomes

Primary

Measure	Time frame
Severity of disease. Timepoint: before intervention and every week until one month. Method of measurement: observation.;IL-6. Timepoint: before intervention and every week until one month. Method of measurement: Elisa.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFarahzad Jabbari-Azad

Mashhad University of Medical Sciences

jabbarif@mums.ac.ir+98 51 3801 2298

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026